# Strattera (atomoxetine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/atomoxetine

> The PDUFA target action date for Strattera (atomoxetine), sponsored by Apnimed, Inc. (APMD), is February 28, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Strattera (atomoxetine) PDUFA date?

The PDUFA target action date for Strattera (atomoxetine), sponsored by Apnimed, Inc. (APMD), is February 28, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi, and assigned a PDUFA target action date of February 28, 2027" Last confirmed September 8, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/atomoxetine)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-385355, https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-09-08. Cite: https://sec-api.dev/pdufa/atomoxetine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Strattera (atomoxetine) |
| Codes | APC-002 |
| Sponsor | Apnimed, Inc. (APMD) https://sec-api.dev/companies/apmd/catalysts |
| Indications | with obstructive sleep apnea |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 8, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: with obstructive sleep apnea.
- First seen 2026-09-08, last confirmed 2026-09-08.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-385355): "Announced the FDA accepted for review the New Drug Application ("NDA") for AD109 (proposed proprietary name Oxnimbi) for the treatment of adults with obstructive sleep apnea ("OSA")." https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm

### February 28, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-07-31, last confirmed 2026-09-08.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-385355): "U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi, and assigned a PDUFA target action date of February 28, 2027" https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-385355): ""This was a highly productive quarter for Apnimed as we continued to execute against our strategy, highlighted by the FDA's acceptance of our NDA for AD109 (proposed proprietary name Oxnimbi), with a PDUFA target action date of February 28, 2027," said Kevin Lind, Chief Executive Officer of Apnimed." https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-385355): "The FDA has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-385355): "Apnimed's NDA for Oxnimbi is under review by the FDA and was assigned a PDUFA goal date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-385356): "The FDA review cycle is targeted to be 10-months from our NDA submission in April 2026, and the FDA has issued a Prescription Drug User Fee Act ("PDUFA") goal date of February 28, 2027, although the duration of the review may vary based on various factors." https://www.sec.gov/Archives/edgar/data/1745648/000119312526385356/apmd-20260630.htm
- SEC prospectus (424B) (accession 0001193125-26-328422): "The FDA review cycle is targeted to be 10-months from our NDA submission in April 2026, and the FDA has issued a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027, although the duration of the review may vary based on various factors." https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm
- SEC prospectus (424B) (accession 0001193125-26-328422): "The FDA assigned a PDUFA goal action date of February 28, 2027." https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm
- SEC prospectus (424B) (accession 0001193125-26-328422): "The FDA review cycle is targeted to be 10-months from our NDA submission in April 2026, and the FDA has issued a PDUFA goal date of February 28, 2027, although the duration of the review may vary based on various factors." https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm
- SEC prospectus (424B) (accession 0001193125-26-328422): "The FDA review cycle is targeted to be 10-months from our NDA submission in April 2026, and the FDA has issued a PDUFA goal date of February 28, 2027, although the duration of the review may vary based on various factors.The FDA does not always meet its PDUFA goal dates for standard or priority NDAs and the review process is often extended by FDA requests for additional information or clarification." https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/atomoxetine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Strattera (atomoxetine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/atomoxetine

```bibtex
@misc{secapidev_pdufa_atomoxetine_20261116,
  title        = {Strattera (atomoxetine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/atomoxetine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_atomoxetine_20261116","title":"Strattera (atomoxetine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/atomoxetine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
